SAC-253
Oncology (broad potential)
Key Facts
About Saccharo
Saccharo is a private, preclinical-stage biotech leveraging a novel, serendipitously discovered immune evasion pathway centered on the polysaccharide dPSA. The company's core hypothesis is that dPSA, re-expressed on cancer cells and associated with surface nucleolin, represents a highly specific and conserved target that could overcome limitations of protein-targeted therapies, such as off-target toxicity and resistance. Its pipeline, led by the ADC candidate SAC-253, is being advanced through a recent collaboration with Memorial Sloan Kettering, supported by a leadership team with deep industry experience from top biopharma firms. Saccharo's approach aims to create therapies with a broad potential application across solid and hematologic cancers.
View full company profile